Allogene Therapeutics
South San Francisco
CA
United States
155 articles with Allogene Therapeutics
-
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
3/14/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it will present interim data from its Phase 1 TRAVERSE trial of ALLO-316, the Company’s first AlloCAR T candidate for solid tumors, in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place in April in Orlando, Florida.
-
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
3/2/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences.
-
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
3/1/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of a case review in Molecular Therapy of the single patient treated with ALLO-501A who presented with a chromosomal rearrangement.
-
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
2/28/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter and year ended December 31, 2022.
-
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
2/21/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report fourth quarter and year-end 2022 financial results on Tuesday, February 28, 2023, after the close of the market.
-
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
2/1/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, presented preclinical data highlighting the Company’s next generation DaggerTM platform technology at the Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy Keystone Symposia in Banff, Alberta, Canada.
-
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
1/25/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of a preclinical study demonstrating delta-like ligand 3 (DLL3) is a promising tumor target for AlloCAR T™ in small cell lung cancer (SCLC).
-
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
1/24/2023
Allogene Therapeutics, Inc. today announced that data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory (r/r) multiple myeloma (MM) has been published in Nature Medicine.
-
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences - Jan 17, 2023
1/17/2023
Allogene Therapeutics, Inc. announced that it will participate in two upcoming investor conferences.
-
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Allogene Therapeutics, Inc. today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:45 p.m. Pacific Time.
-
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
1/3/2023
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced the appointment of Zachary J. Roberts M.D., Ph.D. to Executive Vice President of Research and Development.
-
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
11/29/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today hosted an R&D Showcase providing an extensive overview of pipeline advances from three clinical stage AlloCAR T programs.
-
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
11/10/2022
Allogene Therapeutics, Inc. today presented pre-clinical data on a novel approach to immune “cloaking” designed to protect AlloCAR T™ cells from rapid host rejection.
-
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
11/9/2022
Allogene Therapeutics, Inc. will host a Research & Development Showcase to provide a comprehensive overview of its CD19 and BCMA programs on November 29, 2022.
-
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
11/3/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it will present updated data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory multiple myeloma, in a poster presentation at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10-13, 2022 in New Orleans, LA.
-
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
11/2/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter ended September 30, 2022.
-
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
10/31/2022
Allogene Overland Biopharm, a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced it has completed the buildout of its state-of-the-art AlloCAR T manufacturing facility in Shanghai, China.
-
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
10/26/2022
Allogene Therapeutics, Inc. today announced that it will report third quarter 2022 financial results on Wednesday, November 2, 2022, after the close of the market.
-
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide
10/11/2022
Allogene Therapeutic today launched CAR T Together™, a first-of-its-kind effort comprised of leading clinical trial investigators who represent the field of clinicians committed to supporting the development of “off-the-shelf” (allogeneic) chimeric antigen receptor (CAR) T products to make CAR T therapy scalable and more accessible to patients with certain cancers.
-
Allogene Therapeutics is launching what it calls the first pivotal Phase II trial of an allogeneic CAR T product in the industry. The ALPHA2 trial will evaluate ALLO-501A in LBCL.